Nilotinib (Tasigna) versus imatinib (Gleevec) for newly diagnosed, previously untreated chronic myelogenous leukemia (Early Chronic Phase)

Research output: Contribution to journalArticle

Original languageEnglish (US)
Number of pages1
JournalP and T
Volume34
Issue number2
StatePublished - Feb 1 2009
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{f2ba1ba3c23b439e951e81d0d5eee1c2,
title = "Nilotinib (Tasigna) versus imatinib (Gleevec) for newly diagnosed, previously untreated chronic myelogenous leukemia (Early Chronic Phase)",
author = "Jorge Cortes",
year = "2009",
month = "2",
day = "1",
language = "English (US)",
volume = "34",
journal = "P and T",
issn = "1052-1372",
publisher = "MediMedia USA Inc.",
number = "2",

}

TY - JOUR

T1 - Nilotinib (Tasigna) versus imatinib (Gleevec) for newly diagnosed, previously untreated chronic myelogenous leukemia (Early Chronic Phase)

AU - Cortes, Jorge

PY - 2009/2/1

Y1 - 2009/2/1

UR - http://www.scopus.com/inward/record.url?scp=62149113360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62149113360&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:62149113360

VL - 34

JO - P and T

JF - P and T

SN - 1052-1372

IS - 2

ER -